Cargando…
Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Treatment with biological agents has become standard of care in treatment of immune-mediated diseases (IMD), including rheumatoid arthritis and psoriatic arthritis. Yet, a significant proportion of patients experience loss of response to biologics, need treatment escalation, or develop side effects....
Autores principales: | Furer, Victoria, Elkayam, Ori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rambam Health Care Campus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147400/ https://www.ncbi.nlm.nih.gov/pubmed/37116059 http://dx.doi.org/10.5041/RMMJ.10494 |
Ejemplares similares
-
Comorbidities in Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2017) -
Pseudoseptic Arthritis: An Initial Presentation of Underlying Psoriatic Arthritis
por: Paul, Prodip, et al.
Publicado: (2021) -
Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study
por: Rotar, Ziga, et al.
Publicado: (2020) -
Idiopathic Eosinophilic Vasculitis: Case Presentation and Literature Review
por: Broyde, Adi, et al.
Publicado: (2023) -
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
por: Uhrenholt, Line, et al.
Publicado: (2019)